MeteoWeb
EMA’s safety committee, the Prac, is reviewing data on the risk of suicidal thoughts and thoughts of self-harm with medicines known as Glp-1 receptor agonists, including Ozempic (semaglutide), Saxenda (liraglutide) and Wegovy (semaglutide). These are drugs used for weight loss and for the treatment of type 2 diabetes. The review – reads a note from the European Medicines Agency – was initiated by the Icelandic medicines agency following reports of suicidal thoughts and self-harm in people using liraglutide and semaglutide medicines.
So far, the authorities have recovered and are analyzing about 150 reports of possible cases of self-harm and suicidal thoughts. “The drugs liraglutide and semaglutide are in widespread use, with exposure of more than 20 million patient-years to date. It is not yet clear whether the reported cases are related to the drugs themselves or to the patients’ underlying conditions or other factors.”explains the EMA.
“The review is ongoing as part of a referral process. A signal is information about a new adverse event potentially caused by a medicinal product or a new aspect of a known adverse event that requires further investigation. The presence of a signal does not necessarily mean that a medicinal product caused the adverse event in question.” it needs.
The review of Ozempic, Saxenda and Wegovy began on July 3 and has now been extended to include other Glp-1 receptor agonists. The review is expected to conclude in November 2023.
Follow MeteoWeb on Google News